New treatments for bladder cancer: When will we make progress?

Current Treatment Options in Oncology

Volumn 15, Issue 1, 2014, Pages 99-114

  Nadal, Rosa ^a   Bellmunt, Joaquim ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Bladder cancer; Molecular markers; Targeted therapies; Urothelial tumors

Indexed keywords

APATORSEN; BEVACIZUMAB; BUPARLISIB; CABOZANTINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CIXUTUMUMAB; DOCETAXEL; DOVITINIB; ENZYME INHIBITOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; GEMCITABINE; GSK 2126458; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; PACLITAXEL; PAZOPANIB; PGX 427; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; VANDETANIB; VINFLUNINE;

ANGIOGENESIS; ARTICLE; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; DRUG TARGETING; HUMAN; MONOTHERAPY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; STRESS, PHYSIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84894667942     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-013-0271-3     Document Type: Article

References (86)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
2. Bellmunt J, Choueiri TK, Fougeray R, Schutz FA, Salhi Y, Winquist E, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol. 2010;28:1850-5. This study reports pretreatment prognostic factors for overall survival in patients with metastatic transitional cell carcinoma of the urothelial tract that experienced treatment failure with the first-line platinum-based regimen.
3. Kamat AM, Hegarty PK, Gee JR, Clark PE, Svatek RS, Hegarty N, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers. Eur Urol. 2012;63:4-15.
4. Sjodahl G, Lauss M, Gudjonsson S, Liedberg F, Hallden C, Chebil G, et al. A systematic study of gene mutations in urothelial carcinoma: inactivating mutations in TSC2 and PIK3R1. PLoS One. 2011;6:e18583.
5. Lindgren D, Sjodahl G, Lauss M, Staaf J, Chebil G, Lovgren K, et al. Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. PLoS One. 2012;7:e38863.
6. Iyer G, Al-Ahmadie H, Schultz N, Hanrahan AJ, Ostrovnaya I, Balar AV, et al. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol. 2013;31:3133-40.
7. Al-Ahmadie HA, Iyer G, Janakiraman M, Lin O, Heguy A, Tickoo SK, et al. Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma. J Pathol. 2011;224:270-9.
8. Taylor BS, Barretina J, Socci ND, Decarolis P, Ladanyi M, Meyerson M, et al. Functional copy-number alterations in cancer. PLoS One. 2008;3:e3179.
9. Gui Y, Guo G, Huang Y, Hu X, Tang A, Gao S, et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet. 2011;43:875-8.
10. Solomon DA, Kim JS, Bondaruk J, Shariat SF, Wang ZF, Elkahloun AG, et al. Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet. 2013; [Epub ahead of print]. doi: 10.1038/ng.2800.
11. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602-8. This study comparing gemcitabine- cisplatin with M-VAC demonstrated similar levels of activity in the metastatic setting, but with an improved safety profile vs M-VAC.
12. Sternberg CN, de Mulder P, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF vs classic M-VAC in advanced urothelial tract tumours. Eur J Cancer. 2006;42:50-4.
13. Bamias A, Karadomou A, Lampaki S, et al. Prospective, randomized Phase III study comparing two intensified regimens (methothexate/vinblastine/ doxorrubicin hydrochloride/cisplatin (MVAC) vs gemcitabine/cisplatin) in patients with inoperable or recurrent urothelial cancer. 2011 ASCO Annual Meeting Abstracts; J Clin Oncol 29:15s, 2011 (suppl, abstr 4510).
14. Bellmunt J, von der Maase H, Mead GM, Skoneczna I, De Santis M, Daugaard G, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol. 2012;30:1107-13.
15. Sternberg CN, Skoneczna IA, Castellano D, Theodore C, Blais N, Voog E, et al. Larotaxel with cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB). Oncology. 2013;85:208-15.
16. De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012;30:191-9.
17. st line in CDDP-unfit patients (pts) with urothelial carcinoma (UC): VFL/Gemcitabine vs. VFL/CBDCA in a randomized international phase II trial (JASINT 1). ECCO meeting 2013; [abstract # 2703].
18. Pronzato P, Vigani A, Pensa F, Vanoli M, Tani F, Vaira F. Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer. Am J Clin Oncol. 1997;20:519-21.
19. Lorusso V, Pollera CF, Antimi M, Luporini G, Gridelli C, Frassineti GL, et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer. 1998;34:1208-12.
20. Shidhar SS. A phase II study of single-agent nab-paclitaxel as second-line therapy in patients with metastatic urothelial carcinoma. 2010 ASCO Annual Meeting Abstracts; J Clin Oncol 28:15s, 2010 (suppl, abstr TPS231).
21. Bellmunt J, Theodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27:4454-61.
22. Dominguez-Escrig JL, Kelly JD, Neal DE, King SM, Davies BR. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. Clin Cancer Res. 2004;10:4874-84.
23. Nagasawa J, Mizokami A, Koshida K, Yoshida S, Naito K, Namiki M. Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo. Int J Urol. 2006;13:587-92.
24. Nutt JE, Lazarowicz HP, Mellon JK, Lunec J. Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2. Br J Cancer. 2004;90:1679-85.
25. Lichtner RB, Wiedemuth M, Noeske-Jungblut C, Schirrmacher V. Rapid effects of EGF on cytoskeletal structures and adhesive properties of highly metastatic rat mammary adenocarcinoma cells. Clin Exp Metastasis. 1993;11:113-25.
26. Petrylak DP, Tangen CM, Van Veldhuizen Jr PJ, Goodwin JW, Twardowski PW, Atkins JN, et al. Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU Int. 2010;105:317-21.
27. Philips GK, Halabi S, Sanford BL, Bajorin D, Small EJ. A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. Ann Oncol. 2009;20:1074-9.
28. Pea G. Randomized phase II trial of gemcitabine/cisplatin (GC) with or without cetuximab (CET) in patients (pts) with advanced urothelial carcinoma (UC) [abstract]. J Clin Oncol. 2012;30(Suppl):a4506.
29. Wong YN, Litwin S, Vaughn D, Cohen S, Plimack ER, Lee J, et al. Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. J Clin Oncol. 2012;30:3545-51.
30. Pruthi RS, Nielsen M, Heathcote S, Wallen EM, Rathmell WK, Godley P, et al. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. BJU Int. 2010;106:349-54.
31. Black PC, Brown GA, Inamoto T, Shrader M, Arora A, Siefker-Radtke AO, et al. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res. 2008;14:1478-86.
32. Blehm KN, Spiess PE, Bondaruk JE, Dujka ME, Villares GJ, Zhao YJ, et al. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin Cancer Res. 2006;12:4671-7.
33. Lae M, Couturier J, Oudard S, Radvanyi F, Beuzeboc P, Vieillefond A. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol. 2010;21:815-9.
34. Hussain MH, MacVicar GR, Petrylak DP, Dunn RL, Vaishampayan U, Lara Jr PN, et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol. 2007;25:2218-24. This phase II trial reports the safety and efficacy (response rates, time to disease progression, survival) of trastuzumab, carboplatin, gemcitabine, and paclitaxel in HER2-positive advanced urothelial carcinoma patients.
35. Beuzeboc P et al. Trastuzumab (T) combined with standard chemotherapy in HER + metastatic bladder cancer (BC) patients: interim safety results of a prospective randomized phase II study [abstract]. J Clin Oncol. 2007;25(Suppl):a15565.
36. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01353222 2013.
37. US National Library of Medicine. ClinicalTrials.gov [online], < http://clinicaltrials.gov/show/NCT00238420. 2013.
38. Wulfing C, Machiels JP, Richel DJ, Grimm MO, Treiber U, De Groot MR, et al. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer. 2009;115:2881-90.
39. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00949455 2012.
40. di Martino E, Tomlinson DC, Knowles MA. A Decade of FGF Receptor research in bladder cancer: past, present, and future challenges. Adv Urol. 2012:429213.
41. Lamont FR, Tomlinson DC, Cooper PA, Shnyder SD, Chester JD, Knowles MA. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer. 2011;104:75-82.
42. Milowsky Mea. Final results of a multicenter, open-label phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated FGFR3 [abstract]. J Clin Oncol. 2013;31:a255
43. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01732107 2013.
44. Williams SV, Hurst CD, Knowles MA. Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet. 2013;22:795-803.
45. Rochester MA, Patel N, Turney BW, Davies DR, Roberts IS, Crew J, et al. The type 1 insulin-like growth factor receptor is over-expressed in bladder cancer. BJU Int. 2007;100:1396-401.
46. McKian KP, Haluska P. Cixutumumab. Expert Opin Investig Drugs. 2009;18:1025-33.
47. Platt FM, Hurst CD, Taylor CF, Gregory WM, Harnden P, Knowles MA. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res. 2009;15:6008-17.
48. Lopez-Knowles E, Hernandez S, Malats N, Kogevinas M, Lloreta J, Carrato A, et al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res. 2006;66:7401-4.
49. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01551030 2013.
50. Munster P. PI3K kinase inhibitor GSK2126458 (GSK458): clinical activity in select patient (PT) populations defined by predictive markers (study P3K112826) [abstract]. Ann Oncol. 2012;23:a4420.
51. Hansel DE, Platt E, Orloff M, Harwalker J, Sethu S, Hicks JL, et al. Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma. Am J Pathol. 2010;176:3062-72.
52. Seront E, Rottey S, Sautois B, Kerger J, D'Hondt LA, Verschaeve V, et al. Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann Oncol. 2012;23:2663-70.
53. Milowsky MI, Iyer G, Regazzi AM, Al-Ahmadie H, Gerst SR, Ostrovnaya I, et al. Phase II study of everolimus in metastatic urothelial cancer. BJU Int. 2013;112:462-70.
54. Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338:221. This study points out promising clinical activity observed especially in patients harboring TSC1 mutations.
55. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01215136 2013.
56. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00933374 2013.
57. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00949949 2013.
58. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01184326 2013.
59. Kopparapu PK, Boorjian SA, Robinson BD, Downes M, Gudas LJ, Mongan NP, et al. Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer. Anticancer Res. 2013;33:2381-90.
60. Inoue K, Slaton JW, Kim SJ, Perrotte P, Eve BY, Bar-Eli M, et al. Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. Cancer Res. 2000;60:2290-9.
61. Afonso J, Santos LL, Amaro T, Lobo F, Longatto-Filho A. The aggressiveness of urothelial carcinoma depends to a large extent on lymphovascular invasion-the prognostic contribution of related molecular markers. Histopathology. 2009;55:514-24.
62. Hahn NM, Stadler WM, Zon RT, Waterhouse D, Picus J, Nattam S, et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol. 2011;29:1525-30.
63. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00942331 2013.
64. Dreicer R, Li H, Stein M, DiPaola R, Eleff M, Roth BJ, et al. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer. 2009;115:4090-5.
65. Sridhar SS, Winquist E, Eisen A, Hotte SJ, McWhirter E, Tannock IF, et al. A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. Invest New Drugs. 2011;29:1045-9.
66. Sonpavde G, Periman PO, Bernold D, Weckstein D, Fleming MT, Galsky MD, et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol. 2010;21:319-24.
67. Bellmunt J, Gonzalez-Larriba JL, Prior C, Maroto P, Carles J, Castellano D, et al. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann Oncol. 2011;22:2646-53.
68. Gallagher DJ, Al-Ahmadie H, Ostrovnaya I, Gerst SR, Regazzi A, Garcia-Grossman I, et al. Sunitinib in urothelial cancer: clinical, pharmacokinetic, and immunohistochemical study of predictors of response. Eur Urol. 2011;60:344-9.
69. Galsky MD, Hahn NM, Powles T, Hellerstedt BA, Lerner SP, Gardner TA, et al. Gemcitabine, cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer. 2013;11:175-81.
70. Necchi A, Mariani L, Zaffaroni N, Schwartz LH, Giannatempo P, Crippa F, et al. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol. 2012;13:810-6.
71. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01622660 2013.
72. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01108055 2013.
73. Choueiri TK, Ross RW, Jacobus S, Vaishampayan U, Yu EY, Quinn DI, et al. Double-blind, randomized trial of docetaxel plus vandetanib vs docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol. 2012;30:507-12.
74. Bottaro DP, Liotta LA. Cancer: out of air is not out of action. Nature. 2003;423:593-5.
75. Cheng HL, Trink B, Tzai TS, Liu HS, Chan SH, Ho CL, et al. Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation. J Clin Oncol. 2002;20:1544-50.
76. Sanchez-Carbayo M, Socci ND, Lozano JJ, Haab BB, Cordon-Cardo C. Profiling bladder cancer using targeted antibody arrays. Am J Pathol. 2006;168:93-103.
77. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol. 2006;24:778-89.
78. Apolo AB, Cecchi F, et al. Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC). J Clin Oncol. 2013;31.
79. US National Library of Medicine. ClinicalTrials.gov [online], < http://clinicaltrials.gov/show/NCT01688999 > 2012.
80. Richardson PG, Mitsiades CS, Laubach JP, Lonial S, Chanan-Khan AA, Anderson KC. Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br J Haematol. 2011;152:367-79.
81. Kamada M, So A, Muramaki M, Rocchi P, Beraldi E, Gleave M. Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. Mol Cancer Ther. 2007;6:299-308.
82. Kanagasabai R, Karthikeyan K, Vedam K, Qien W, Zhu Q, Ilangovan G. Hsp27 protects adenocarcinoma cells from UV-induced apoptosis by Akt and p21-dependent pathways of survival. Mol Cancer Res. 2010;8:1399-412.
83. Concannon CG, Gorman AM, Samali A. On the role of Hsp27 in regulating apoptosis. Apoptosis. 2003;8:61-70.
84. Garg M, Kanojia D, Seth A, Kumar R, Gupta A, Surolia A, et al. Heat-shock protein 70-2 (HSP70-2) expression in bladder urothelial carcinoma is associated with tumor progression and promotes migration and invasion. Eur J Cancer. 2010;46:207-15.
85. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01454089 (2013). 2013.
86. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01780545 2013.